Alette M. Wessels
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Health Systems, Economic Evaluations, Quality of Life, Bipolar Disorder and Treatment, Cholinesterase and Neurodegenerative Diseases
Most-Cited Works
- → Donanemab in Early Symptomatic Alzheimer Disease(2023)2,261 cited
- → Donanemab in Early Alzheimer’s Disease(2021)1,598 cited
- → Diabetic encephalopathy: a concept in need of a definition(2006)208 cited
- → Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease(2019)194 cited
- → Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy(2006)176 cited
- → Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume(2007)131 cited
- → Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes(2008)109 cited
- → Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease(2020)90 cited
- → A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS)(2015)80 cited
- → Microvascular Disease in Type 1 Diabetes Alters Brain Activation(2006)71 cited